Multiple Sclerosis

The agency has also approved the baclofen oral suspension for Azurity Pharmaceuticals to treat individuals with other spinal cord diseases or injuries.

The researchers projected that approximately 14 participants would experience a significant worsening of their walking function, however, only 8 participants had their walking function decline.

Study results suggest that infection with Epstein-Barr virus may be the leading cause of multiple sclerosis.

Inhibiting the activity of group 3 innate lymphoid cells could serve as a new therapeutic approach for neurologic conditions.

Diagnosis, treatment options, and the role of the pharmacist in patient care are all important factors when looking at multiple sclerosis as a whole.

Agency gives green light to supplemental new drug application for repository corticotropin injection.

According to the investigators, these new data support ofatumumab as a first-choice treatment for adult patients with RMS, including those who are newly diagnosed.

Gyang and Hansen discussed any new or existing treatment options for patients, the role of the pharmacist changing, and what they wish others knew about MS.

Early intervention with ocrelizumab resulted in a 35% reduction of risk in individuals with RMS who needed a walking aid over 7 and a half years.

The 5 largest specialty therapeutic groups—oncology, autoimmune, immunology, HIV, and multiple sclerosis—will account for 74% of specialty spending growth over the next five years.

Although there was a numerical difference between the mean number of new or newly enlarging T2 hyperintense lesions at week 72 of 0.05 (Q4W) and 0.20 (Q6W), this difference was not clinically meaningful in the context of the full data, according to the investigators.